Evidence map›Paper›PMID 42259835›Full record

ArticleNPJ vaccines2026

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.

Paula Freixeiro, Lisa A Lewis, Leonor Sánchez-Busó, Magnus Unemo, Sunita Gulati, Aline Linder, Jukka Corander, Odile B Harrison, Christina Dold, Simon Harris and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Frontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paula FreixeiroJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Lisa A LewisUniversity of Massachusetts, Worcester, MA, USA.
Leonor Sánchez-BusóJoint Research Unit 'Infection and Public Health, Institute for Integrative Systems Biology (I2SysBio), FISABIO-University of Valencia, Valencia, Spain.
Magnus UnemoWHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden.
Sunita GulatiUniversity of Massachusetts, Worcester, MA, USA.
Aline LinderOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Jukka CoranderInstitute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Odile B HarrisonNuffield Department of Population Health, University of Oxford, Oxford, UK.
Christina DoldOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Simon HarrisWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.
Christine S RollierOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Sanjay RamCenter for Scientific Review, National Institutes of Health, Bethesda, MD, USA.
Calman A MacLennanJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. calman.maclennan@ndm.ox.ac.uk.

Funding

BactiVac BVNCP2-10Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator 06CARB-X0948Wellcome Trust 201075/Z/16/Z
6 · The paper itself

Abstract

Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31-59% effectiveness. We hypothesised that gonococcal OMV-based vaccines would have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560lpxL1

Identifiers

PMID42259835
PMCPMC13315605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.